// App-Quantinova.ai

e21006 : A Prospective Analysis of High-Dose Interleukin-2 (HD IL-2) following PD-1 inhibitor therapy in patients with metastatic melanoma and renal cell carcinoma.

Researchers

Presenter

  • Elizabeth Iannotti Buchbinder

Principal Investigators

  • Janice P. Dutcher

  • Jessica C. Perritt

  • Joseph Clark

  • Shernan G. Holtan

  • John M. Kirkwood

  • Brendan D. Curti

  • Christopher D. Lao

  • Howard Kaufman

  • Mayer N. Fishman

  • David F. McDermott

Medical Centers

  • Dana-Farber Cancer Institute, Boston, MA

  • Our Lady of Mercy Cancer Center, New York, NY

  • Prometheus Laboratories Inc., San Diego, CA

  • Loyola University Medical Center, Maywood, IL

  • Mayo Clinic, Rochester, MN

  • Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA

  • Earle A Chiles Research Institute, Providence Portland Medical Center, Portland, OR

  • University of Michigan, Ann Arbor, MI

  • Rush University Medical Center, Chicago, IL

  • Moffitt Cancer Center, Tampa, FL

  • Beth Israel Deaconess Medical Center, Boston, MA

Locations

  • United States

Companies

  • Prometheus Laborator

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Renal cell carcinoma

  • Melanoma

  • Solid malignancies

Biomarkers

  • Programmed cell death protein 1

  • Interleukin-2

Drug/Treatment

  • Interleukin

Outcome

  • N/A

Study Design

  • Observational

  • Prospective

  • Cohort

Phase

  • NA

Study Id's

  • NCT01415167

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved